ArticleCancer cell international2017
Avenanthramide-C reduces the viability of MDA-MB-231 breast cancer cells through an apoptotic mechanism.
Article in Cancer cell international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 48 citations in OpenAlex.
- Metformin treatment impairs the adenine nucleotide translocator activity and energy metabolism in human clear cell renal carcinoma cells.Scientific reports · 2026Article
- Synthesis of Avenanthramide C and Its Analogs Utilizing Classical Condensation, Saponification and Acidification.ACS omega · 2026Article
- Double-Edged Sword Effect of Diet and Nutrition on Carcinogenic Molecular Pathways in Breast Cancer.International journal of molecular sciences · 2024Review
- Synthesis and Evaluation of a Monomethyl Auristatin E─Integrin αJournal of medicinal chemistry · 2023Article
- Apoptotic and antiproliferative effects of silk protein sericin conjugated-AgNOSaudi journal of biological sciences · 2023Article
- Optimization of chemical conditions for metabolites production byFrontiers in microbiology · 2023Article
- Pharmacological and In Silico Analysis of Oat Avenanthramides as EGFR Inhibitors: Effects on EGF-Induced Lung Cancer Cell Growth and Migration.International journal of molecular sciences · 2022Article
- Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma.Cell death & disease · 2022Article
- Computational study, synthesis and evaluation of active peptides derived from Parasporin-2 and spike protein from Alphacoronavirus against colorectal cancer cells.Bioscience reports · 2021Article
- Mediterranean Diet and Physical Activity: Two Imperative Components in Breast Cancer Prevention.Cureus · 2021Review
- Avenanthramide C Suppresses Matrix Metalloproteinase-9 Expression and Migration Through the MAPK/NF- κB Signaling Pathway in TNF-α-Activated HASMC Cells.Frontiers in pharmacology · 2021Article
- Avenanthramides as lipoxygenase inhibitors.Heliyon · 2020Article
- Overview of the Anticancer Profile of Avenanthramides from Oat.International journal of molecular sciences · 2019Review
- Review
- Avenanthramide C from germinated oats exhibits anti-allergic inflammatory effects in mast cells.Scientific reports · 2019Article
- Cytoprotective effects of Avenathramide C against oxidative and inflammatory stress in normal human dermal fibroblasts.Scientific reports · 2019Article
- Yeast-Derived Recombinant Avenanthramides Inhibit Proliferation, Migration and Epithelial Mesenchymal Transition of Colon Cancer Cells.Nutrients · 2018Article
- Biological Activities, Health Benefits, and Therapeutic Properties of Avenanthramides: From Skin Protection to Prevention and Treatment of Cerebrovascular Diseases.Oxidative medicine and cellular longevity · 2018Review
- Synergetic effect of doxorubicin and avenanthramide C on VDAC2/MTCH1 mitochondrial axis in breast cancer cells.International journal of health sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAvenanthramides (AVN) are a relatively unstudied family of phytochemicals that could be novel chemotherapeutics. These compounds, found in oats, are non-toxic to healthy cells and have been shown to reduce viability of human colon and liver cancers in vitro. However, these studies do not elucidate a molecular mechanism for individual AVN. In this study we aim to see the effects of AVN on MDA-MB-231 breast cancer cells.
methodsAn MTT assay was used to determine cell viability. Staining and analysis with a flow cytometer was used to identify cell cycle progression and apoptosis. FloJo software was used to analyze the cytometric data. In all experiments, statistical significance was determined by a two-tailed t test.
resultsThis study demonstrates that AVN-A, B, and C individually reduce viability in the MDA-MB-231 breast cancer cell line. AVN-C has the most potent decrease in tumor cell viability, decreasing viable cells to below 25% at 400 µM when compared to control after 96 h. We demonstrate that treatment with AVN-C causes DNA fragmentation and accumulation of over 90% of cells into a sub G
conclusionsBreast cancer cells treated with AVN-C have a decrease in cell viability, an increase in the sub G
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.